NRx Pharmaceuticals announced that President Trump signed an executive order on April 18 2026 to accelerate the approval of psychedelic drugs, a development that directly benefits the company’s NRX‑100 program.
The order directs the FDA to issue National Priority Vouchers for drugs with Breakthrough Therapy designation and calls for collaboration with the Department of Veterans Affairs and the private sector. NRX‑100, a preservative‑free intravenous ketamine for suicidal ideation in depression, has Fast Track designation and is preparing a New Drug Application for June 2026.
The company reported a net loss of $28.9 million and a stockholders’ deficit of $25.8 million, and it has a $150 million shelf to support future financing. The executive order could reduce regulatory timelines and lower development costs, improving the company’s financial outlook.
CEO Jonathan C. Javitt said, “We thank President Trump, Secretary Kennedy, and Commissioner Makary for their leadership and decisive action to address America’s mental health crisis, particularly the devastating toll of PTSD and suicide among our veterans.” He added that the order “provides a clear path to expedite the review of NRX‑100 and aligns with our mission to deliver life‑saving treatments for patients with severe mental illness.”
The order also allocates $50 million for federal‑state collaboration and encourages real‑world evidence generation. NRx plans to leverage existing clinical trial data and real‑world evidence to meet the FDA’s requirements, potentially avoiding additional trials and accelerating market entry.
With the voucher program and the executive order’s emphasis on rapid review, NRx expects the regulatory process to shorten, which could bring NRX‑100 to patients sooner and strengthen its competitive position in the emerging psychedelic therapeutics market.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.